

Subject, city, state	Effective date	Subject, city, state	Effective date	Subject, city, state	Effective date
N OLMSTED, OH		OMAHA, NE		OCONOMOWOL, WI	
DEFAULT ON HEAL LOAN		MONICA, JULIANNE H	02/20/2002	Dated: March 4, 2002.	
ALEXANDER, MICHAEL A	02/20/2002	SPRING LAKE, NJ	02/20/2002	Calvin Anderson, Jr.,	
ALQUIPPA, PA		NEWELL, DAVID CLIFFORD ...	02/20/2002	<i>Director, Health Care Administrative</i>	
ARGUEDAS, WALTER G	02/20/2002	FORT BRAGG, CA	02/20/2002	<i>Sanctions, Office of Inspector General.</i>	
HIALEAH, FL		OWCZAREK, KEITH VINCENT	02/20/2002	[FR Doc. 02-5944 Filed 3-12-02; 8:45 am]	
BELLER, BRYAN D	02/20/2002	MARYSVILLE, WA	02/20/2002	BILLING CODE 4150-04-P	
SOUTHGATE, MI		PATT, RICHARD H	02/20/2002	DEPARTMENT OF HEALTH AND HUMAN SERVICES	
CAFAGNA, MARK WILLIAM		NEW YORK, NY	02/20/2002		
SR	02/20/2002	PEISS, STUART	02/20/2002	National Institutes of Health	
WEST HILLS, CA		HOFFMAN ESTATES, IL		Proposed Collection; Comment Request; Policies of Academic Institutions Regarding Tobacco Industry Research Funding	
CAGLE, LARRY S	02/20/2002	PHILLIPS, THADDEUS	02/20/2002		
AHOSKIE, NC		HILLARD III	02/20/2002	SUMMARY: In compliance with the	
CARR, GUY A	02/20/2002	SAN ANTONIO, TX			
HUTCHINSON, KS		PORTNOW, ROBERT THOMAS	02/20/2002	requirement of Section 3506(c)(2)(A) of	
CONSTANTINESCU, SERBAN		AS	02/20/2002		
CRISTIA	02/20/2002	CLEVELAND, OH		the Paperwork Reduction Act of 1995,	
PHILADELPHIA, PA		RAMU, NALAYA	02/20/2002		
COOPER, SHIRLEY T	02/20/2002	LOS ANGELES, CA	02/20/2002	for opportunity for public comment on	
LANSDALE, PA		RASHTI, KOUROS	02/20/2002		
CRAIG, BRADLEY D	02/20/2002	TARZANA, CA		proposed data collection projects, the	
SNOWFLAKE, AZ		RICHBERG, MARK H	02/20/2002		
DE JESUS-MIRANDA, LUIS A		PHILADELPHIA, PA	02/20/2002	national Cancer Institute (NCI), the	
SAN JUAN, PR		RIGNEY, MARK EDWARD	02/20/2002		
DIENER, ROBERT B	02/20/2002	OKLAHOMA CITY, OK	02/20/2002	National Institutes of Health (NIH) will	
AUBURNDALE, MA		ROMERO, JOHN JOSEPH	02/20/2002		
DONELSON, RICHARD BAR-		ALBUQUERQUE, NM	02/20/2002	publish periodic summaries of proposed	
TON	02/20/2002	RORRER, MARK TIMOTHY ...	02/20/2002		
PHOENIX, AZ		CLAYTON, OH		projects to be submitted to the Office of	
EATON, GARY D	02/20/2002	ROZENBERG, RONALD L	02/20/2002		
SPRINGFIELD, MO		LEVITTOWN, NY	02/20/2002	Management and Budget (OMB) for	
ELLZEY, PAUL D	02/20/2002	RUSSELL, BILL	02/20/2002		
PRATTVILLE, AL		ST LOUIS, MO	12/18/2001	review and approval.	
FISHBOUGH, ROSS E	02/20/2002	SAID, SAED M			
BENSLAEM, PA		DUNIONVILLE, CT	02/20/2002	Proposed Collection	
FLOYD, THOMAS PARKER ...	02/20/2002	SANDOR, GEORGE JOSEPH	02/20/2002	<i>Title:</i> Policies of Academic	
TRUFANT, MI		NEW YORK, NY	02/20/2002		
GREETHONG, KITIMAN	02/20/2002	SAUTMAN, SATPAL K	02/20/2002	Institutions Regarding Tobacco Industry	
IRVINE, CA		PLANTATION, FL	02/20/2002		
HAGEN, CALVIN P	02/20/2002	SCHWARTZ, FRANCIS XA-	02/20/2002	<i>Type of Information Collection</i>	
KANSAS CITY, MO		VIER JR	02/20/2002		
HANSEN, KRIS T	02/20/2002	OAKLAND, CA		<i>Request:</i> NEW.	
ST GEORGE, UT		SCHWARZ-MANDRACCHIA,	02/20/2002		
HORNIG-ROHAN, JAMES ED-		DENISE MA	02/20/2002	<i>Need and Use of Information</i>	
WARD	02/20/2002	WINTERSET, IA	02/20/2002		
SENECA, SC		SLOTNICK, ROBIN T	02/20/2002	<i>Collection:</i> This study will assess	
IBRIK, AMIR	02/20/2002	CLEVELAND, OH	02/20/2002		
SYRACUSE, NY		STOCK, ANN M	02/20/2002	current administrative policies of	
KALMAN, BETSY S	02/20/2002	BELLEVILLE, IL	02/20/2002		
RICHMOND HILL, NY		THOMPSON, JANETTE A	02/20/2002	medical schools and schools of public	
KRUGMAN, LINDA L	02/20/2002	SILVER SPRING, MD	02/20/2002		
LEXINGTON, KY		TOLIVER, EDWARD C	02/20/2002	health regarding faculty acceptance of	
LE SAGE, SAHARA ADAMS ...	02/20/2002	CHICAGO, IL	02/20/2002		
LEAGUE CITY, TX		VESTICH, GEORGE T	02/20/2002	research funding from tobacco	
LEONELLI, DAVID ROMAN SR		RICHMOND, OH	02/20/2002		
LOS ANGELES, CA		VILLANO, GUY JOHN	02/20/2002	manufacturers and trade organizations.	
LEWIS, STEVEN R	02/20/2002	NISKAYUNA, NY	02/20/2002		
IRVING, TX		WALCHER, KEVIN RAY	02/20/2002	The primary objectives of the study are	
LINSTEADT, ELIZABETH M ...	02/20/2002	BOOKER, TX	02/20/2002		
DENISON, TX		WALTERS, BRIAN D JR	02/20/2002	to assess how many institutions have a	
LUCEY, TIMOTHY D	02/20/2002	SEATTLE, WA	02/20/2002		
NEWBURGH, NY		WAN, JAMES Y	02/20/2002	tobacco-specific research funding	
MARTINEZ, DANIEL A	02/20/2002	MOBILE, AL	02/20/2002		
REDLANDS, CA		WHEDBEE, JOSEPH IRE-	02/20/2002	policy, their reasons for adopting or not	
MASSAKOWSKI, EDWARD A		LAND	02/20/2002		
BENSALEM, PA		REDLANDS, CA	02/20/2002	adopting such a policy, and what the	
MCGHEE, STEPHANIE Y	02/20/2002	WILLIAMS, ERIC A	02/20/2002		
HOUSTON, TX		TOWSON, MD	02/20/2002	requirements of those policies are. The	
MCINNES, THOMAS K	02/20/2002	WILSON, RONALD E	02/20/2002		
POOLESVILLE, MD		DETROIT, MI	02/20/2002	finding will provide valuable	
MEINHOLD, STEVEN DALE ...	02/20/2002	YODER, KYLE JAY	02/20/2002		
		REDWOOD CITY, CA	02/20/2002	information concerning: (1) How	
		ZIMMERMAN, MARY L P	02/20/2002		

The annual reporting burden is as follows:

Estimated Number of Respondents: 156.

Estimated Number of Responses per Respondent: 1.

Average Burden Hours Per Response: .5.

Estimated Total Annual Burden Hours Requested: 78.

The annualized cost to respondents is estimated at: \$780. There are no Capital Costs to report. There are no Operating or Maintenance Costs to report.

Request for Comments

Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

FOR FURTHER INFORMATION CONTACT: To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact Dr. Mark Parascandola, Cancer Prevention Fellow, OPO, DCP, NCI, NIH, 6130 Executive Boulevard, Suite 3109, Bethesda, MD 20892, or call non-toll-free number (301) 594-1576 or E-mail your request, including your address to: paramark@mail.nih.gov.

Comments Due Date

Comments regarding this information collection are best assured of having their full effect if received on or before May 13, 2002.

Dated: February 19, 2002.

Reesa L. Nichols,

NCI Project Clearance Liaison.

[FR Doc. 02-5930 Filed 3-12-02; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Artificial Chromosomes That Can Shuttle Between Bacteria, Yeast, and Mammalian Cells

Larionov et al. (NCI)

DHHS Reference No. E-253-00/0 filed April 6, 2001

Licensing Contact: Pradeep Ghosh; 301/496-7736 ext. 211; e-mail ghoshp@od.nih.gov.

Development of a novel cloning system in mammalian cells based on Mammalian Artificial Chromosome (MAC) may have profound effects on human gene therapy. The technology described in invention pertains to methods and compositions that allow for the selective isolation of centromeric regions from mammalian chromosomes, including those of humans. Also included in the invention are cloned and characterized centromeric regions of humans and other mammalian chromosomes. The isolation of these centromeric regions provides a material for engineering of MACs that are capable of being shuttled between bacterial, yeast and mammalian cells, such as human cells. These MACs may serve as effective tools for the characterization of cis-active loci controlling transmission of mammalian

chromosomes. The present invention has broad utilities in studies related to genetic diseases. It can be used for studying of expression of entire copies of human genes. Gene therapy may have therapeutic and preventative applications and a range of gene therapy approaches are currently being evaluated for treatment of cancer and a large number of autoimmune and genetic disorders. Gene therapy necessitates an efficient system for gene delivery. The MACs constructed in this invention provide useful vehicles for the delivery and expression of transgenes within cells. Thus, the present invention provides a novel method allowing a direct isolation of mammalian centromeres and efficient system for gene delivery associated with gene therapy.

Treatment of Pain Based on Parathyroid Hormone-2 (PTH2) Receptors

Ted B. Usdin (NIMH)

DHHS Reference No. E-079-01/0 filed Jun 13 2001

Licensing Contact: Norbert Pontzer; 301/496-7736 ext. 284; e-mail: np59n@nih.gov.

Current medications for pain, especially chronic pain, are only partially effective and can involve unacceptable side effects. A unique receptor (PTH2) and an endogenous ligand (TIP39) which binds to the receptor were previously discovered by this inventor. The PTH2 receptor and the endogenous ligand were found to have an anatomical distribution suggesting a role in nociception. The PTH2 receptor is present at relatively high levels in nerve terminals within the outer layers of the dorsal horn of the spinal cord where it is primarily coupled to generation of cAMP (Usdin, T.B., et al., 1999, *Nature Neurosci.* 2: 941-943; Wang, T., et al., 2000, *Neuroscience* 100: 629-49; Usdin, T.B., et al., 2000, *Front Neuroendocrinol* 21: 349-83) The DRG neurons that project to this area are largely nociceptors and this region contains the central nervous system neurons they activate. Most receptors present in the central terminals of DRG neurons are also found in their peripheral terminals. Thus, activation of the PTH2 receptor could modulate peripheral excitation of nociceptors, neurotransmitter release from their central terminals in the spinal cord, and some of their postsynaptic effects.

This inventor has now shown the PTH2 receptor system to have very potent actions in animal tests of nociception. Both peripheral and